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Summary
Objective: We conducted the present study to determine the level of physical activ-
ity required to retard the progression of carotid intima-media thickness (IMT) in
patients with coronary heart disease (CHD).
Patients and main outcome measurements: The daily walking distance (km/day) of
40 patients with CHD (male/female ratio: 37/3, mean age: 61.2 years, mean interval
time after a coronary event 16.2 months) was examined. Carotid IMT examinations
(B-mode ultrasonography) were performed at the baseline and after 6 months.
Results: Among the patients, the average walking distance was 4.00 km/day. Walking
distance was inversely associated with IMT progression (r =−0.51, p < 0.01). Mul-
tivariate logistic regression analysis revealed that walking distance (p = 0.024) is
a predictor for IMT progression independent of classical cardiovascular risk fac-
tors. Receiver operating characteristic analysis showed that the walking distance
of 4.25 km was strongly predictive of IMT preservation (sensitivity 64.0%, speciﬁcity
73.3%) in CHD patients.
Conclusions: Our data suggested that an increase in the daily walking distance could
retard the progression of carotid IMT in patients with CHD. Cardiology medical staff
should encourage their patients to expend an average of 4—5 km in daily walking
distance for the secondary prevention of cardiovascular disease.
© 2008 Published by Elsevie
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easurements of carotid intima-media thickness
IMT) have been used previously for the noninvasive
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detection of carotid atherosclerosis lesions. A
thickened IMT is correlated empirically with the risk
of future cardiovascular events, such as myocardial
infarction and stroke [1]. Furthermore, a previous
autopsy study has identiﬁed a relationship of thick-
ened IMT with the grade of lesion severity in the
carotid and other arteries [2]. These interrelations
suggest that IMT may serve as a surrogate variable
when studying general atherosclerosis.
It is generally accepted that physical activity and
exercise training have an antiatherogenic effect
[3] that may be related to a reduction in the
progression of IMT. Only a few studies have been
conducted on the effect of increased physical activ-
ity on IMT. A diet-and-exercise intervention slowed
menopause-related IMT progression [4]. Physically
sedentary hypertensive patients were shown to
have signiﬁcantly greater levels of IMT than active
hypertensive patients [5]. To our knowledge, there
are no guidelines on the physical activity level nec-
essary to retard IMT progression. We conducted
the present study to determine the level of phys-
ical activity required to retard IMT progression in
patients with coronary heart disease (CHD).
Methods
Patients
The study population consisted of 40 eligible
patients with stable CHD, aged 45—79 years (mean
age: 61.2± 7.13 years), who were admitted to the
Department of Rehabilitation Medicine in Saitama
Medical University Hospital between September
2004 and April 2005. These patients visited our
hospital for a health counseling and an exercise
prescription. Of these patients, 23 had undergone
percutaneous transluminal coronary angiography
(PTCA) previously and the other 17 had under-
gone coronary artery bypass grafting (CABG); the
mean interval time after the coronary event was
16.2± 12.3 months. Inclusion criteria were who had
carotid plaque, deﬁned as focal IMT > 1.1mm in the
CCA and bifurcation, but no symptoms of carotid
artery disease. Exclusion criteria included uncon-
trolled heart failure, severe or unstable angina
pectoris, and uncontrolled hypertension, hyper-
lipidemia or diabetes mellitus. To reduce the
confounding effects of disease on the capacity to
walk, patients with stroke and intermittent clau-
dication were excluded. Patients, who were not
able to appear for check-up visits, and patients
refusing to give their written consent, were also
excluded.
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aseline examination
t the baseline, all patients underwent a full
hysical examination to obtain the body mass
ndex (BMI), systolic blood pressure (SBP), and
eak oxygen uptake, which were measured by
ardiac pulmonary exercise testing (CPX). CPX
as performed in the upright position on a bicy-
le ergometer (Strength Ergo 8, Fukuda Denshi,
okyo, Japan) with an initial workload of 0Watt
W), with subsequent increments of 15W every
inute until exhaustion. Expired gas exchange dur-
ng symptom-limited exercise testing was measured
y breath-by-breath analysis with a metabolic cart
AE300s, MINATO, Tokyo, Japan). From these mea-
urements, oxygen uptake was calculated every
0 s.
For the assessment of physical activity, infor-
ation on the amount of daily walking distance
as collected by a trained interviewer [6]. All
atients were asked about the average distance
hey walked per day. Additional characteristics
ncluded age, gender, and history of hyperten-
ion (deﬁned as systolic blood pressure >140mmHg
r diastolic blood pressure >90mmHg or antihy-
ertensive treatment), diabetes (deﬁned with the
apan diabetes society criteria published in 1999
7]), and hyperlipidemia (deﬁned as blood triglyc-
rides >150mg/dl or blood total cholesterol levels
220mg/dl or treatment with statins).
arotid ultrasound
arotid ultrasound examinations were performed at
he baseline and after 6 months. Details of data
ollection and evaluation methods for IMT of the
ommon carotid artery have been published else-
here [8,9]. In brief, one trained technician with
o knowledge of the treatment assignment per-
ormed all the examinations. Ultrasonography was
erformed with the patients in the supine position,
sing a CF-sonic UF7500 (Fukuda-Denshi, Tokyo,
apan) with a 7.5MHz transducer. The IMT was
eﬁned as the distance between the leading edge of
he lumen-intima echo and the leading edge of the
edia-adventitia echo. Measurements of carotid
MT were performed on the far walls of the com-
on carotid artery (CCA). IMT was calculated as the
verage value of the IMT measurements for six sites
three on each side) in the CCA. The examinations
ere video-graphic printed with a micro-caliper for
ubsequent analyses. To evaluate the validity of the
ltrasonographic method, we performed repeated
cans of the same patients 6 times within 1 month.
he average difference in IMT among these mea-
urements was 2.43% of the mean IMT. The change
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Table 1 Demographic and clinical characteristics for changes in relative IMT after 6 months of study
All patients (n = 40) Progression of IMT (n = 15, 37.5%) No progression of IMT (n = 25, 62.5%) p
IMT at baseline (mm) 0.92± 0.18 0.95± 0.19 0.90± 0.17 0.73
IMT (mm) 0.01± 0.05 0.057± 0.04 −0.018± 0.03 <0.01
Distance walked (km/day) 4.00± 1.8 3.18± 1.7 4.49± 1.7 0.03
Cardiovascular risk factors
Age (year) 61.2± 7.1 59.2± 9.5 59.2± 5.8 0.19
Gender (n) female (%) 3 (7.5) 1(6.7) 2 (8) 0.88
BMI (kg/m2) 24.3± 2.0 24.4± 1.5 24.3± 2.3 0.87
SBP (mmHg) 127.3± 19.7 136.7± 17.6 121.6± 19.0 0.02
Peak VO2 (ml/(min kg) 20.5± 4.3 20.4± 4.5 20.5± 4.3 0.98
Hypertension (n) (%) 30 (75) 12 (80) 18 (72) 0.57
Diabetes (n) (%) 19 (47.5) 9 (47.4) 10 (52.6) 0.22
Hyperlipidemia (n) (%) 25 (62.5) 7 (46.7) 18 (72) 0.11
Medications
ACE inhibitors (n) (%) 21 (52.5) 10 (66.7) 11 (44) 0.17
-Blockers (n) (%) 30 (74) 12 (80) 18 (72) 0.57
Calcium-channel blockers (n) (%) 2 (5) 1 (6.7) 1 (4) 0.71
Aspirin (n) (%) 35 (87.5) 14 (93.3) 21 (84) 0.39
Statis user (n) (%) 18 (40) 5 (33.3) 13 (52) 0.25
S. Sato et al.
Figure 1 Correlation of walking distance and change in
intima-media thickness (IMT).
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in IMT (IMT = IMT after 6 months—–IMT at baseline)
within 6 months was used as an index of IMT pro-
gression. Furthermore, we dichotomized responses
into ‘‘patients with progression (IMT > 0mm)’’ or
‘‘without progression (IMT≤ 0mm)’’.
Statistical analysis
All values were expressed as the mean± standard
deviation. Difference between groups were
assessed by using the t-test or 2 test as appro-
priate. Correlations between the ranges of IMT
changes and daily walking distance were evaluated
by calculating Pearson’s correlation coefﬁcients.
Forward multiple logistic regression analysis was
performed to detect independent risk factors
for the progression of IMT. Receiver operating
characteristic (ROC) analysis was constructed
for variables retained in the multivariate Cox
regression analysis. Optimal cut-off values (highest
combination of sensitivity/speciﬁcity) of daily
walking distance were identiﬁed for the course
of IMT progression via ROC analysis. A value of
p < 0.05 was regarded as signiﬁcant.
Results
All of the 40 enrolled patients fully completed the
study. During the study period, medical treatment
and physical activity was maintained almost con-
stant, and no episodes of severe clinical events
were recorded. The basic clinical characteristics
are given in Table 1.
At the baseline, the average walking dis-
tance was 4.00± 1.8 km/day. Walking distance
was inversely associated with the IMT as
a marker of disease progression (r =−0.51,
p < 0.01; Fig. 1). The patients were divided in
two groups retrospectively: patients with pro-
gression (n = 15, mean IMT = 0.057± 0.04mm)
and those without progression (n = 25, mean
IMT =−0.018± 0.03mm). Patients with pro-
gression had a signiﬁcant lower walking distance
(3.18± 1.7 vs. 4.49± 1.7 km; p = 0.03) and higher
SBP (136.7± 17.6 vs. 121.6± 19.0mmHg; p = 0.02)
than patients without progression (Table 1).
To identify possible mechanisms for the observed
changes in IMT, baseline characteristics, includ-
ing cardiovascular risk factors, medications and
walking distance, were analyzed in terms of their
relation to the IMT progression. The best multiple
linear regressions model for predicting the IMT pro-
gression included the walking distance (p = 0.024)
and resting SBP (p = 0.030).
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1igure 2 Receiver—operator characteristic curved for
etection of IMT preservation by measures of walking
istance.
ROC analysis showed that the walking distance of
.25 km was strongly predictive of IMT preservation
sensitivity 64.0%, speciﬁcity 73.3%) (Fig. 2).
iscussion
he ﬁndings of this study indicated that enhanced
hysical activity is negatively correlated with the
rogression of carotid atherosclerosis lesions eval-
ated as mean IMT in patients with stable CHD.
his result further supports the importance of phys-
cal activity for improving general atherogenesis
n CHD patients. Additionally, our data suggested
hat patients who walked more than 4.25 km/day
ad signiﬁcantly reduced progression of carotid IMT.
ambrecht et al. showed that even in patients
ith CHD who walked the equivalent to at least
533 kcal/week, the beneﬁcial effect of walking
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Rhysical activity and IMT in CHD patients
n coronary atherosclerosis lesions persisted [10].
n average, 1533 kcal/week must be expended,
mounting to 4—5 km/day of walking distance. The
ombined results of the present and previous stud-
es suggest that the amount of 4—5 km/day of
alking distance in leisure time physical activity
s necessary to retard the progression of general
therosclerosis in patients with CHD.
There have been very few clinical trials on the
ssociation between physical activity and IMT pro-
ression. The Women’s Healthy Lifestyle Project
WHLP) trial reported that a diet-and-exercise
ntervention slowed menopause-associated IMT
rogression among women who had reached the
eri-menopause or post-menopause period [4]. This
ttempt was made to examine only healthy women.
ccordingly, this is the ﬁrst study showing that a
igher activity level results in a markedly reduced
MT progression in patients with CHD.
The mechanism by which high-level physical
ctivity induced favorable changes in IMT remains
bscure. Previous trials suggest that the lipid-
owering effect is a key element in carotid
therosclerosis regression. In the regression growth
valuation statin study (REGRESS) [11], the effects
f pravastatin treatment on the mean and maxi-
al IMT of men with CHD were highly signiﬁcant. In
ther lipid intervention studies, treatment effects
ere also signiﬁcant [12—14]. The interventional
pproach to reducing insulin resistance also could
esult in the regression of carotid atherosclero-
is. A prospective study on pioglitazone therapy
n patients with type 2 diabetes resulted in
signiﬁcant decrease in mean IMT [15]. It is
enerally accepted that physical activity and exer-
ise training improved the serum lipid proﬁle,
nsulin resistance and other metabolic disorders.
hus, improvement in several components of the
etabolic risk factors jointly may be associated
ith a markedly reduced IMT progression in the
igh-level physical activity group.
In the REGRESS trial, relative regression of the
ean IMT was 6—7% in 2 years [11]. Riegger et
l. demonstrated that 52-week aggressive ﬂuvas-
atin therapy led to mean IMT regression of 2—3% in
atients with CHD [16]. Accordingly, the regression
f mean IMT in the high-level physical activity group
n our study seemed to be of the same order of mag-
itude as regression achieved with high-dose statin
herapy in patients with CHD. However, we predict
hat this excellent beneﬁt was achieved not only
y the walking, but also through good lipid control
nd statin use greater than 50% in the high-level
hysical activity group.
Our study had several limitations. Carotid IMT
s now widely accepted as a validated surrogate161
arker for carotid atherosclerotic lesions [11,17].
et, there is no generally accepted standardized
ethod for measuring IMT. In our examination,
nly the IMT data of images of the far walls
ere analyzed. The latter is justiﬁed by the bet-
er reproducibility of measurements from this site
nd the difﬁculties in obtaining measurements from
he near walls. Since we were interested mainly
n progression/regression of general atheroscle-
osis, we did not record the maximal IMT and
he shape and quality of plaque, but measured
he mean IMT at a deﬁned location. It is likely
hat each of these markers has a different role
o play in the evaluation of atherosclerosis [18].
urther studies are needed to investigate the
ose-dependent effects of physical activity on
he maximal IMT and plaque formation. In addi-
ion, we did not obtain relevant clinical data
or the atherosclerotic risk factors, such as LDL
holesterol, HDL cholesterol, fasting serum glu-
ose, fasting serum insulin and HbA1c. Therefore,
ur analysis, which was adjusted for these inter-
ediate risk factors, may have underestimated
he effect of physical activity on IMT progression.
nother limitation of our study was the self-
eported physical activity. Using a self-reported
uestionnaire to assess lifestyle habits is gen-
rally a crude approach. Misclassiﬁcation might
esult in an overestimation of the relationship
etween physical activity and IMT changes in our
tudy.
Nonetheless, our data suggested that an increase
n the daily walking distance could retard the pro-
ression of carotid atherosclerotic lesions in CHD
atients. Cardiology medical staff should encour-
ge their patients to expend an average of 4—5 km
n daily walking distance for the secondary preven-
ion of cardiovascular disease.
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